ES2380990T3 - Derivados de azabiciclo[3.1.0]hexano útiles como moduladores de los receptores D3 de dopamina - Google Patents

Derivados de azabiciclo[3.1.0]hexano útiles como moduladores de los receptores D3 de dopamina Download PDF

Info

Publication number
ES2380990T3
ES2380990T3 ES08169935T ES08169935T ES2380990T3 ES 2380990 T3 ES2380990 T3 ES 2380990T3 ES 08169935 T ES08169935 T ES 08169935T ES 08169935 T ES08169935 T ES 08169935T ES 2380990 T3 ES2380990 T3 ES 2380990T3
Authority
ES
Spain
Prior art keywords
methyl
propyl
thio
triazol
hexane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08169935T
Other languages
English (en)
Spanish (es)
Inventor
Luca; Bonanomi Giorgio Arista
Anna Maria; Damiani Federica Capelli
Romano; Gentile Gabriella Di Fabio
Dieter; Micheli Fabrizio Hamprecht
Luca; Tedesco Giovanna Tarsi
Silvia Terreni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0403990A external-priority patent/GB0403990D0/en
Priority claimed from GB0404083A external-priority patent/GB0404083D0/en
Priority claimed from GB0417120A external-priority patent/GB0417120D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2380990T3 publication Critical patent/ES2380990T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES08169935T 2004-02-23 2005-02-21 Derivados de azabiciclo[3.1.0]hexano útiles como moduladores de los receptores D3 de dopamina Active ES2380990T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0403990 2004-02-23
GB0403990A GB0403990D0 (en) 2004-02-23 2004-02-23 Compounds
GB0404083 2004-02-24
GB0404083A GB0404083D0 (en) 2004-02-24 2004-02-24 Compounds
GB0417120 2004-07-30
GB0417120A GB0417120D0 (en) 2004-07-30 2004-07-30 Compounds

Publications (1)

Publication Number Publication Date
ES2380990T3 true ES2380990T3 (es) 2012-05-22

Family

ID=34890800

Family Applications (2)

Application Number Title Priority Date Filing Date
ES08169935T Active ES2380990T3 (es) 2004-02-23 2005-02-21 Derivados de azabiciclo[3.1.0]hexano útiles como moduladores de los receptores D3 de dopamina
ES05707610T Active ES2337590T3 (es) 2004-02-23 2005-02-21 Derivados de azabiciclo (3.1.0) hexano utiles como moduladores de los receptores d3 de dopamina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES05707610T Active ES2337590T3 (es) 2004-02-23 2005-02-21 Derivados de azabiciclo (3.1.0) hexano utiles como moduladores de los receptores d3 de dopamina.

Country Status (26)

Country Link
US (3) US7855298B2 (tr)
EP (3) EP2070922B1 (tr)
JP (1) JP4960217B2 (tr)
KR (1) KR101143718B1 (tr)
CN (1) CN1946714B (tr)
AR (1) AR047890A1 (tr)
AT (3) ATE542816T1 (tr)
AU (2) AU2005215918C1 (tr)
BR (1) BRPI0507945A (tr)
CA (1) CA2557115C (tr)
CY (3) CY1109854T1 (tr)
DE (1) DE602005018190D1 (tr)
DK (3) DK1745040T3 (tr)
ES (2) ES2380990T3 (tr)
HK (1) HK1103016A1 (tr)
HR (3) HRP20100114T1 (tr)
IL (1) IL177184A0 (tr)
MA (1) MA28438B1 (tr)
NO (1) NO20064309L (tr)
PE (1) PE20051173A1 (tr)
PL (3) PL2070922T3 (tr)
PT (3) PT1745040E (tr)
RU (1) RU2434011C2 (tr)
SI (3) SI1745040T1 (tr)
TW (1) TW200538113A (tr)
WO (1) WO2005080382A1 (tr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2380990T3 (es) * 2004-02-23 2012-05-22 Glaxo Group Limited Derivados de azabiciclo[3.1.0]hexano útiles como moduladores de los receptores D3 de dopamina
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
WO2006133945A1 (en) 2005-06-14 2006-12-21 Glaxo Group Limited Novel compounds
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
WO2007006117A1 (en) * 2005-07-13 2007-01-18 Nicogen Inc. Novel cyp2a6 inhibitors
AU2006275870B2 (en) 2005-07-27 2013-01-10 Otsuka America Pharmaceutical, Inc. Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517175D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
US7799815B2 (en) * 2005-08-22 2010-09-21 Glaxo Group Limited Triazole derivatives as modulators of dopamine D3 receptors
GB0517191D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
ATE498619T1 (de) * 2006-04-03 2011-03-15 Glaxo Group Ltd Azabicycloä3.1.0ühexanderivate als modulatoren von dopamin-d3-rezeptoren
JP5189076B2 (ja) * 2006-04-03 2013-04-24 グラクソ グループ リミテッド ドーパミンｄ３受容体のモジュレーターとしてのアザビシクロ［３．１．０］ヘキシル誘導体
GB0703387D0 (en) * 2007-02-21 2007-03-28 Glaxo Group Ltd Novel compounds
GB0607899D0 (en) * 2006-04-03 2006-05-31 Glaxo Group Ltd Process for preparing heterocyclic derivatives
JP5189074B2 (ja) * 2006-04-03 2013-04-24 グラクソ グループ リミテッド ドーパミンｄ３受容体のモジュレーターとしてのアザビシクロ［３．１．０］ヘキシル誘導体
GB0608452D0 (en) * 2006-04-27 2006-06-07 Glaxo Group Ltd Novel compounds
US20080045725A1 (en) 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
GB0616574D0 (en) * 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds
US8138377B2 (en) 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US20090069374A1 (en) * 2007-06-06 2009-03-12 Phil Skolnick Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
GB0719234D0 (en) * 2007-10-02 2007-11-14 Glaxo Group Ltd Novel compounds
GB0719235D0 (en) 2007-10-02 2007-11-14 Glaxo Group Ltd Novel compounds
EP2481737A1 (en) 2008-06-24 2012-08-01 Merck Sharp & Dohme Corp. Biocatalytic processes for the preparation of substantially stereomerically pure fused bicyclic proline compounds
US8536185B2 (en) * 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
CN102803224A (zh) * 2009-06-26 2012-11-28 万能药生物有限公司 新的氮杂双环己烷类化合物
EP3068226A4 (en) * 2013-11-11 2017-05-17 Euthymics Bioscience, Inc. Novel methods
ES2821896T3 (es) 2015-08-05 2021-04-28 Indivior Uk Ltd Antagonistas del receptor de dopamina D3 que tienen una unidad estructural biciclo
US11447484B2 (en) 2018-01-26 2022-09-20 Shionogi & Co., Ltd. Cyclic compound having dopamine D3 receptor antagonistic effect
MX2022016445A (es) 2020-06-22 2023-02-01 Corcept Therapeutics Inc Antagonistas del receptor de glucocorticoides de indazol cuaternario.
WO2023122594A1 (en) * 2021-12-21 2023-06-29 Corcept Therapeutics Incorporated Bicyclic indazole glucocorticoid receptor antagonists

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR022229A1 (es) * 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion
GB0015562D0 (en) * 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
US7429579B2 (en) 2000-11-14 2008-09-30 Smithkline Beecham, Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents)
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
AP1816A (en) 2001-10-22 2008-01-04 Pfizer Prod Inc 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists.
EP1529045A2 (en) * 2002-08-09 2005-05-11 Astra Zeneca AB New compounds
ES2380990T3 (es) * 2004-02-23 2012-05-22 Glaxo Group Limited Derivados de azabiciclo[3.1.0]hexano útiles como moduladores de los receptores D3 de dopamina
GB0507602D0 (en) 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
WO2006133945A1 (en) 2005-06-14 2006-12-21 Glaxo Group Limited Novel compounds
GB0517191D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
US7799815B2 (en) * 2005-08-22 2010-09-21 Glaxo Group Limited Triazole derivatives as modulators of dopamine D3 receptors
GB0517175D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
JP5189074B2 (ja) 2006-04-03 2013-04-24 グラクソ グループ リミテッド ドーパミンｄ３受容体のモジュレーターとしてのアザビシクロ［３．１．０］ヘキシル誘導体
GB0616574D0 (en) * 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
US20100152195A1 (en) 2010-06-17
ATE520686T1 (de) 2011-09-15
AU2005215918B2 (en) 2009-06-11
NO20064309L (no) 2006-11-23
HRP20120281T1 (hr) 2012-04-30
DK1745040T3 (da) 2010-04-12
RU2434011C2 (ru) 2011-11-20
HRP20110781T1 (hr) 2011-11-30
PL1745040T3 (pl) 2010-05-31
CY1113029T1 (el) 2016-04-13
EP2060570A3 (en) 2009-06-03
CN1946714A (zh) 2007-04-11
AU2005215918A1 (en) 2005-09-01
HRP20100114T1 (hr) 2010-04-30
US7855298B2 (en) 2010-12-21
EP1745040B9 (en) 2010-06-02
KR20060127991A (ko) 2006-12-13
US20070142438A1 (en) 2007-06-21
PL2070922T3 (pl) 2012-01-31
KR101143718B1 (ko) 2012-07-05
ATE451364T1 (de) 2009-12-15
EP2070922B1 (en) 2011-08-17
IL177184A0 (en) 2006-12-10
JP4960217B2 (ja) 2012-06-27
DE602005018190D1 (de) 2010-01-21
ATE542816T1 (de) 2012-02-15
CN1946714B (zh) 2011-06-15
SI2070922T1 (sl) 2011-12-30
JP2007523208A (ja) 2007-08-16
EP1745040A1 (en) 2007-01-24
RU2006133909A (ru) 2008-03-27
CA2557115C (en) 2012-10-02
CA2557115A1 (en) 2005-09-01
CY1109854T1 (el) 2014-09-10
PT1745040E (pt) 2010-03-08
TW200538113A (en) 2005-12-01
HK1103016A1 (en) 2007-12-14
AU2009212887A1 (en) 2009-09-24
SI2060570T1 (sl) 2012-05-31
US8283474B2 (en) 2012-10-09
PE20051173A1 (es) 2006-02-14
BRPI0507945A (pt) 2007-07-24
MA28438B1 (fr) 2007-02-01
PT2060570E (pt) 2012-05-07
DK2060570T3 (da) 2012-04-30
AR047890A1 (es) 2006-03-01
DK2070922T3 (da) 2011-11-28
EP1745040B1 (en) 2009-12-09
ES2337590T3 (es) 2010-04-27
PL2060570T3 (pl) 2012-06-29
PT2070922E (pt) 2011-11-24
CY1112011T1 (el) 2015-11-04
EP2060570B1 (en) 2012-01-25
EP2070922A1 (en) 2009-06-17
WO2005080382A1 (en) 2005-09-01
US20100160336A1 (en) 2010-06-24
SI1745040T1 (sl) 2010-04-30
AU2005215918C1 (en) 2010-01-21
EP2060570A2 (en) 2009-05-20
US8263782B2 (en) 2012-09-11

Similar Documents

Publication Publication Date Title
ES2380990T3 (es) Derivados de azabiciclo[3.1.0]hexano útiles como moduladores de los receptores D3 de dopamina
ES2339274T3 (es) 3-triazoliltioalquil-3-azabiciclo(3-1-o)hexanos y su uso como ligandospara los receptores d3 de dopamina.
US7947683B2 (en) 3-(1,2,4-triazol-3-ylalkyl) azabicyclo (3.1.0) hexane derivatives as modulators of dopamine D3 receptors
ES2355056T3 (es) Derivados de azabiciclo[3.1.0]-hexano como moduladores del receptor d3 de dopamina.
ES2358445T3 (es) Derivados de azabiciclo (3.1.0) hexano útiles como moduladores de los receptores d3 de dopamina.
ES2327162T3 (es) Derivados de azabicilo(3,1,0)hexano utiles como moduladores de los receptores de dopamina d3.
CA3215949A1 (en) Oxazepine compounds and uses thereof in the treatment of cancer
KR20230051227A (ko) 헤테로아릴 치환된 스피로피페리디닐 유도체 및 이의 제약 용도
ES2378861T3 (es) Derivados de azabiciclo[3.1.0]hexilo como moduladores de los receptores D3 de la dopamina
ES2356843T3 (es) Derivados de triazol como moduladores de los receptores d3 de dopamina.
MXPA06009652A (en) Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
ES2361201T3 (es) Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores d3 de dopamina.
BR112016004909B1 (pt) Compostos espirocíclicos como inibidores de triptofano hidroxilase, composição farmacêutica e seus usos